ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
December 09, 2020 22:26 ET
|
ALX Oncology
BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
ALX Oncology Announces Proposed Public Offering of Common Stock
December 07, 2020 16:08 ET
|
ALX Oncology
BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma
December 07, 2020 10:00 ET
|
ALX Oncology
-- ORR of 70.0% Observed in Patients with NHL Treated with Higher Doses of ALX148 with Median Duration of Response Not Yet Reached -- Significant Improvement in Clinical Response Demonstrated with...
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
December 07, 2020 07:00 ET
|
ALX Oncology
-- Due to the registration potential of two planned Phase 2 head and neck cancer studies, FDA has requested completion of a standard ongoing non-clinical safety study -- Initiation of planned Phase...
ALX Oncology Announces December 2020 Virtual Investor Conference Participation
November 24, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights
November 12, 2020 16:05 ET
|
ALX Oncology
BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
November 09, 2020 08:10 ET
|
ALX Oncology
-- ORR of 64% Observed in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- ORR of 75% and One Complete Response Observed in Patients with 1L Head and Neck Cancer --...
ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
November 05, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47...
ALX Oncology Announces November 2020 Virtual Investor Conference Participation
November 02, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47...
ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
October 28, 2020 07:00 ET
|
ALX Oncology
BURLINGAME, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47...